| Name | Title | Contact Details |
|---|
Somatic Therapies is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
JSR Life Sciences is a business unit of JSR Corporation, a global company built on more than 50 years of performance material expertise and it began research in the life sciences field more than 30 years ago. We are continually developing highly functional materials and products to meet the current and future needs of the growing biotechnology industry. Using a variety of integrated, leading-edge technologies, JSR Life Sciences provides materials that contribute to the manufacturing process of biopharmaceuticals, life science research applications, in vitro diagnostics and medical devices. JSR Life Sciences has offices, laboratories and manufacturing facilities in Tokyo and Tsukuba (JP), Sunnyvale (CA, USA), Leuven (BE) and Beijng (CN). We are a part of the JSR Corporation, an international company employing over 6’000 people worldwide and being a leading materials supplier in a variety of technology driven markets. JSR Corporation`s global network is headquartered in Tokyo (Japan) and has factories and offices all over the world. As a research-oriented organization, JSR Corporation pursues close collaborations with leading innovators in a number of industries that are key to the present and future welfare of human society: life sciences, elastomers, electronic materials, energy storage, display materials and optical materials.
Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103
PsychoGenics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.